REG - AIM - Schedule One - EDX Medical Group PLC

Thermo Fisher ScientificAnnouncement

Today 08:45

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260413:nRSM0545Aa&default-theme=true

RNS Number : 0545A  AIM  13 April 2026

 

 ANNOUNCEMENT TO BE MADE BY THE AIM APPLICANT PRIOR TO ADMISSION IN ACCORDANCE
 WITH RULE 2 OF THE AIM RULES FOR COMPANIES ("AIM RULES")

 COMPANY NAME:

 EDX Medical Group PLC ("the Company or EDX Medical")

 COMPANY REGISTERED OFFICE ADDRESS AND IF DIFFERENT, COMPANY TR

 ADING ADDRESS (INCLUDING POSTCODES):

 211 Cambridge Science Park

 Milton Road

 Cambridge

 Cambs

 England

 CB4 0WA

 COUNTRY OF INCORPORATION:

 Incorporated in England and Wales

 COMPANY WEBSITE ADDRESS CONTAINING ALL INFORMATION REQUIRED BY AIM RULE 26:

 https://edxmedical.co.uk/aim-rule-26/
 (https://can01.safelinks.protection.outlook.com/?url=https%3A%2F%2Fedxmedical.co.uk%2Faim-rule-26%2F&data=05%7C02%7Csandrews%40cgf.com%7C356772df0dbd4ecb3c8a08de97077d60%7C55a8d9e9da724987ac2851b3b5add15f%7C0%7C0%7C639114255685487412%7CUnknown%7CTWFpbGZsb3d8eyJFbXB0eU1hcGkiOnRydWUsIlYiOiIwLjAuMDAwMCIsIlAiOiJXaW4zMiIsIkFOIjoiTWFpbCIsIldUIjoyfQ%3D%3D%7C0%7C%7C%7C&sdata=KjNoxLMa89fuVljE5vcXRj6kqI5gXsroAE972Kg1Z8g%3D&reserved=0)

 COMPANY BUSINESS (INCLUDING MAIN COUNTRY OF OPERATION) OR, IN THE CASE OF AN
 INVESTING COMPANY, DETAILS OF ITS INVESTING POLICY. IF THE ADMISSION IS SOUGHT
 AS A RESULT OF A REVERSE TAKE-OVER UNDER RULE 14, THIS SHOULD BE STATED:
 EDX Medical's main country of operation is the United Kingdom. It develops,
 validates and commercializes innovative digital diagnostic products and
 services, generating valuable biological insights that enable cost effective
 and timely delivery of personalised treatment for cancer, heart disease and
 infectious diseases.

 By translating clinical insights into pragmatic solutions combining advanced
 biological and digital technologies, EDX Medical seeks to improve cost
 effectively the detection and characterisation of disease. The Directors
 believe that early disease detection and biologically-based personal treatment
 optimisation is the most impactful way of improving patient outcomes,
 improving survival and lowering the cost of healthcare globally.

 EDX Medical provides healthcare professionals, providers and payors with
 access to a portfolio of clinical diagnostics products and services that the
 Directors believe represent leading technologies. The Company operates a
 molecular biology and diagnostics laboratory in Cambridge, UK, providing
 testing services accredited to ISO 15189(2022) by the United Kingdom
 Accreditation Service (UKAS) and has strategic product and technology
 partnerships with organisations such as Thermo Fisher EMEA Ltd, which is
 recognised as a world leader in supplying life sciences solutions and
 services.

 DETAILS OF SECURITIES TO BE ADMITTED INCLUDING ANY RESTRICTIONS AS TO TRANSFER
 OF THE SECURITIES (i.e. where known, number and type of shares, nominal value
 and issue price to which it seeks admission and the number and type to be held
 as treasury shares):

 411,844,583 ordinary shares of £0.01 each

 CAPITAL TO BE RAISED ON ADMISSION (AND/OR SECONDARY OFFERING) AND ANTICIPATED
 MARKET CAPITALISATION ON ADMISSION:

 None

 £44.28m

 PERCENTAGE OF AIM SECURITIES NOT IN PUBLIC HANDS AT ADMISSION:

 39.36%

 DETAILS OF ANY OTHER EXCHANGE OR TRADING PLATFORM TO WHICH THE AIM SECURITIES
 (OR OTHER SECURITIES OF THE COMPANY) ARE OR WILL BE ADMITTED OR TRADED:

 The ordinary shares are currently admitted to trading on the Apex Segment of
 Aquis Stock Exchange ("Aquis"). It is expected that trading of the ordinary
 shares on Aquis will be cancelled with effect from admission to AIM

 THE COMPANY HAS APPLIED FOR THE VOLUNTARY CARBON MARKET DESIGNATION (Y/N)

 No

 FULL NAMES AND FUNCTIONS OF DIRECTORS AND PROPOSED DIRECTORS (underlining the
 first name by which each is known or including any other name by which each is
 known):

 Jason Christopher Holt, Non-Executive Chair

 Martin Charles Walton, Deputy Chair

 Dr. Michael ("Mike") Hudson, Chief Executive Officer

 Professor Sir Christopher ("Chris") Thomas Evans, OBE, Chief Science Officer

 Professor Trevor Mervyn Jones, Non-executive Director

 FULL NAMES AND HOLDINGS OF SIGNIFICANT SHAREHOLDERS EXPRESSED AS A PERCENTAGE
 OF THE ISSUED SHARE CAPITAL, BEFORE AND AFTER ADMISSION (underlining the first
 name by which each is known or including any other name by which each is
 known):

 All holdings are the same both pre and post Admission

 Professor Sir Christopher ("Chris") Evans - 136,161,523 - 33.06%

 Bridgemere Securities - 38,970,000 - 9.46%

 West Coast Capital - 31,439,582 - 7.63%

 Countrywide Development Limited - 24,166,667 - 5.87%

 Dr. Michael ("Mike") Hudson - 20,650,000 - 5.01%

 NAMES OF ALL PERSONS TO BE DISCLOSED IN ACCORDANCE WITH SCHEDULE 2, PARAGRAPH
 (H) OF THE AIM RULES:

 None

 (i)         ANTICIPATED ACCOUNTING REFERENCE DATE

 (ii)        DATE TO WHICH THE MAIN FINANCIAL INFORMATION IN THE
 ADMISSION DOCUMENT HAS BEEN PREPARED (this may be represented by unaudited
 interim financial information)

 (iii)       DATES BY WHICH IT MUST PUBLISH ITS FIRST THREE REPORTS
 PURSUANT TO AIM RULES 18 AND 19:

 (i)         31 March

 (ii)        Unaudited interim results to 30 September 2025

 (iii)       By 30 September 2026, 31 December 2026 and 30 September 2027

 EXPECTED ADMISSION DATE:

  13 May 2026

 NAME AND ADDRESS OF NOMINATED ADVISER:

 Canaccord Genuity Limited

 88 Wood Street

 London EC2V 7QR

 NAME AND ADDRESS OF BROKER:

 Canaccord Genuity Limited

 88 Wood Street

 London EC2V 7QR

 OTHER THAN IN THE CASE OF A QUOTED APPLICANT, DETAILS OF WHERE (POSTAL OR
 INTERNET ADDRESS) THE ADMISSION DOCUMENT WILL BE AVAILABLE FROM, WITH A
 STATEMENT THAT THIS WILL CONTAIN FULL DETAILS ABOUT THE APPLICANT AND THE
 ADMISSION OF ITS SECURITIES:

 N/A

 THE CORPORATE GOVERNANCE CODE THE APPLICANT HAS DECIDED TO APPLY

 Quoted Companies Alliance Corporate Governance Code

 DATE OF NOTIFICATION:

 13 April 2026

 NEW/ UPDATE:

 NEW
 QUOTED APPLICANTS MUST ALSO COMPLETE THE FOLLOWING:

 THE NAME OF THE AIM DESIGNATED MARKET UPON WHICH THE APPLICANT'S SECURITIES
 HAVE BEEN TRADED:

 Apex Segment of Aquis Stock Exchange

 THE DATE FROM WHICH THE APPLICANT'S SECURITIES HAVE BEEN SO TRADED:

 29(th) April 2024

 CONFIRMATION THAT, FOLLOWING DUE AND CAREFUL ENQUIRY, THE APPLICANT HAS
 ADHERED TO ANY LEGAL AND REGULATORY REQUIREMENTS INVOLVED IN HAVING ITS
 SECURITIES TRADED UPON SUCH A MARKET OR DETAILS OF WHERE THERE HAS BEEN ANY
 BREACH:

 This is confirmed

 AN ADDRESS OR WEB-SITE ADDRESS WHERE ANY DOCUMENTS OR ANNOUNCEMENTS WHICH THE
 APPLICANT HAS MADE PUBLIC OVER THE LAST TWO YEARS (IN CONSEQUENCE OF HAVING
 ITS SECURITIES SO TRADED) ARE AVAILABLE:

 RNS - EDX Medical (https://edxmedical.co.uk/rns/)

 DETAILS OF THE APPLICANT'S STRATEGY FOLLOWING ADMISSION INCLUDING, IN THE CASE
 OF AN INVESTING COMPANY, DETAILS OF ITS INVESTING STRATEGY:

 EDX Medical is a growing digital diagnostics business, specialised in
 providing diagnostic tests for clinical use which reveal critical information
 to help healthcare professionals and their patients improve clinical
 decision-making and achieve better outcomes. In order to compete successfully
 in the clinical diagnostics sector, EDX Medical has established core
 competencies in the identification, development and validation of tests and
 associated secure data analytical reporting to imminent new UK and European
 regulatory standards. The board believes that these key skills make EDX
 Medical the provider of choice for clients and a strong marketing and
 distribution partner for collaborators.

 EDX Medical provides healthcare professionals, providers and payors with
 access to a portfolio of proprietary diagnostic tests across both 'Laboratory
 Assays' and 'Point of Care' testing - two major segments of the growing global
 clinical diagnostics market, addressing three disease areas of great global
 health and economic impact - cancer, cardiovascular and infectious diseases.
 Both product lines are considered to be capable of addressing large global
 public and private sector markets for improved healthcare testing and secure
 digital reporting.

 The Laboratory Assay portfolio includes market-ready advanced cancer tests
 from world-leading partners under exclusive distribution arrangements
 contributing initial revenues, alongside a growing number of products
 developed by EDX Medical in partnership with Thermo Fisher, with whom EDX
 Medical has a strategic collaboration. EDX Medical is establishing initial
 revenues and product validation in the UK. It is intended that optimised EDX
 Medical products will then be made into kits, validated and submitted for CE-
 IVDR regulatory approval, for sale to laboratories in the public and private
 healthcare sector across Europe, which the Directors believe will create a
 highly scaleable business model.

 The 'Point of Care' test range is based on the patent-pending multiplex test
 platform acquired with Hutano Diagnostics Ltd, which provides highly sensitive
 and quantitative data for multiple key biomarkers in a handheld 20-minute test
 device, with data reporting via mobile phone. Initial applications currently
 in validation include PoC tests for sepsis and prostate cancer.

 ·    Specialist: Focussed on Areas of Significant Global Impact: cancer,
 cardiovascular and infectious diseases,

 ·    Building a Portfolio of Unique and Clinically Validated Assays: 'best
 in class' tests for genetic risk, early disease detection and
 characterisation.

 ·    Early Revenues and Market Access via Distribution Partnerships:
 exclusive partnerships with Caris Life Sciences and with Curesponse Ltd.

 ·    Strong Pipeline via Collaboration with Thermo Fisher proprietary
 assays addressing global needs co-developed based on in-licensed intellectual
 property from Oxford and Cambridge Universities and others.

 ·    Pioneering Multiplex 'Point of Care' Test Platform, Quantitative data
 on multiple biomarkers with digital reporting via mobile phone for sepsis and
 prostate cancers in validation.

 ·    Commercially Scalable Clear commercial growth strategy minimises
 technical and commercial risks, with potential for European expansion in the
 clinical diagnostics market.

 A DESCRIPTION OF ANY SIGNIFICANT CHANGE IN FINANCIAL OR TRADING POSITION OF
 THE APPLICANT, WHICH HAS OCCURRED SINCE THE END OF THE LAST FINANCIAL PERIOD
 FOR WHICH AUDITED STATEMENTS HAVE BEEN PUBLISHED:

 Save as disclosed below there have been no significant changes in the
 financial or trading position of the Company since 30 September 2025 being the
 balance sheet date to which the interims accounts of the Company were made up:

 On 23 October 2025 the Company issued 14,285,713 new Ordinary Shares at a
 price of 14p each to raise £2.0m and entered in to a new convertible loan
 note facility which is available until 9 October 2029 with Sir Chris Evans
 under which a total of £2.0m can be drawn subject to certain conditions. No
 drawings have yet been made on this facility.

 On 20 February 2026 the Company issued 24,999,999 new Ordinary Shares at a
 price of 14p to raise proceeds of £3.5m

 On 13 April 2026 the Company announced a term loan facility of £3.71m from
 Sir Chris Evans to meet the working capital needs of the company, in
 conjunction with the convertible loan note referred to above, for the period
 to 31 December 2027

 A STATEMENT THAT THE DIRECTORS OF THE APPLICANT HAVE NO REASON TO BELIEVE THAT
 THE WORKING CAPITAL AVAILABLE TO IT OR ITS GROUP WILL BE INSUFFICIENT FOR AT
 LEAST TWELVE MONTHS FROM THE DATE OF ITS ADMISSION:

 The Directors have no reason to believe that the working capital available to
 the Company will be insufficient for at least the 12 months from Admission

 DETAILS OF ANY LOCK-IN ARRANGEMENTS PURSUANT TO RULE 7 OF THE AIM RULES:

 None

 A BRIEF DESCRIPTION OF THE ARRANGEMENTS FOR SETTLING THE APPLICANT'S
 SECURITIES:

 Settlement will continue to be through the Euroclear System for dealings in
 Ordinary Shares held in uncertificated form. Ordinary Shares can also be dealt
 with in certificated form.

 A WEBSITE ADDRESS DETAILING THE RIGHTS ATTACHING TO THE APPLICANT'S
 SECURITIES:

 Articles-of-Association-2025-12-08.pdf
 (https://edxmedical.co.uk/wp-content/uploads/2025/12/Articles-of-Association-2025-12-08.pdf)
 and TEXAS Admission Document Final 261022
 (https://edxmedical.co.uk/wp-content/uploads/2022/11/Admission-Document-Final-261022.pdf)

 INFORMATION EQUIVALENT TO THAT REQUIRED FOR AN ADMISSION DOCUMENT WHICH IS NOT
 CURRENTLY PUBLIC:

 The announcement released on 13 April 2026 by EDX entitled "Proposed
 cancellation of Ordinary Shares from the Aquis Stock Exchange and proposed
 application for admission to trading on AIM" contains, inter alia, information
 equivalent to that required for an Admission Document and which is not already
 public.

 A copy of the announcement is available on the Company's website: RNS - EDX
 Medical (https://edxmedical.co.uk/rns/)

 A WEBSITE ADDRESS OF A PAGE CONTAINING THE APPLICANT'S LATEST ANNUAL REPORT
 AND ACCOUNTS WHICH MUST HAVE A FINANCIAL YEAR END NOT MORE THEN NINE MONTHS
 PRIOR TO ADMISSION AND INTERIM RESULTS WHERE APPLICABLE. THE ACCOUNTS MUST BE
 PREPARED IN ACCORDANCE WITH ACCOUNTING STANDARDS PERMISSIBLE UNDER AIM RULE
 19:

 Corporate Documents - EDX Medical (https://edxmedical.co.uk/documents/)

 THE NUMBER OF EACH CLASS OF SECURITIES HELD IN TREASURY:

 NONE

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  PAAIMMITMTTBBTF



            Copyright 2019 Regulatory News Service, all rights reserved